Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

Cyclin K and cyclin D1b are oncogenic in myeloma cells

Authors: Véronique Marsaud, Guergana Tchakarska, Geoffroy Andrieux, Jian-Miao Liu, Doulaye Dembele, Bernard Jost, Joanna Wdzieczak-Bakala, Jack-Michel Renoir, Brigitte Sola

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Aberrant expression of cyclin D1 is a common feature in multiple myeloma (MM) and always associated with mantle cell lymphoma (MCL). CCND1 gene is alternatively spliced to produce two cyclin D1 mRNA isoforms which are translated in two proteins: cyclin D1a and cyclin D1b. Both isoforms are present in MM cell lines and primary cells but their relative role in the tumorigenic process is still elusive.

Results

To test the tumorigenic potential of cyclin D1b in vivo, we generated cell clones derived from the non-CCND1 expressing MM LP-1 cell line, synthesizing either cyclin D1b or cyclin K, a structural homolog and viral oncogenic form of cyclin D1a. Immunocompromised mice injected s.c. with LP-1K or LP-1D1b cells develop tumors at the site of injection. Genome-wide analysis of LP-1-derived cells indicated that several cellular processes were altered by cyclin D1b and/or cyclin K expression such as cell metabolism, signal transduction, regulation of transcription and translation. Importantly, cyclin K and cyclin D1b have no major action on cell cycle or apoptosis regulatory genes. Moreover, they impact differently cell functions. Cyclin K-expressing cells have lost their migration properties and display enhanced clonogenic capacities. Cyclin D1b promotes tumorigenesis through the stimulation of angiogenesis.

Conclusions

Our study indicates that cyclin D1b participates into MM pathogenesis via previously unrevealed actions.
Appendix
Available only for authorised users
Literature
1.
Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J: Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995, 11: 1005-1011.PubMed
2.
Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12: 3499-3511. 10.1101/gad.12.22.3499PubMedCentralCrossRefPubMed
3.
Alt JR, Cleveland JL, Hannink M, Diehl JA: Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 2000, 15: 3102-3114. 10.1101/gad.854900.CrossRef
4.
Lu F, Gladden AB, Diehl JA: An alternative spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003, 63: 7056-7061.PubMed
5.
Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ, Knudsen ES: Cyclin D1 splice variants. J Biol Chem. 2003, 278: 30339-30447. 10.1074/jbc.M303969200CrossRefPubMed
6.
Holley SL, Heighway J, Hoban PR: Induced expression of human CCND1 alternative transcripts in mouse Cyl-1 knockout fibroblasts highlights functional differences. Int J Cancer. 2005, 114: 364-370. 10.1002/ijc.20750CrossRefPubMed
7.
Lin DI, Lessie MD, Gladden AB, Bassing CH, Wagner KU, Diehl JA: Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis. Oncogene. 2008, 27: 1231-1242. 10.1038/sj.onc.1210738PubMedCentralCrossRefPubMed
8.
Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA: Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene. 2006, 25: 998-1007. 10.1038/sj.onc.1209147PubMedCentralCrossRefPubMed
9.
Javiluoma A, Ojala PM: Cell signaling pathways engaged by KSHV. Biochim Biophys Acta. 2006, 1766: 140-158.
10.
Verschuren EW, Hodgson JG, Gray JW, Kogan S, Jones N, Evan GI: The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res. 2004, 64: 581-589. 10.1158/0008-5472.CAN-03-1863CrossRefPubMed
11.
Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM: Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994, 13: 2124-2130.PubMedCentralPubMed
12.
Lovec H, Grzeschiczek A, Kowalski MB, Möröy T: Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994, 13: 3487-3495.PubMedCentralPubMed
13.
Bergsagel PL, Kuehl WM: Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005, 23: 6333-6338. 10.1200/JCO.2005.05.021CrossRefPubMed
14.
Jares P, Colomer D, Campo E: Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007, 7: 750-762. 10.1038/nrc2230CrossRefPubMed
15.
Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E, Nowell P, Deprimo SE, Sadis S, Eck S, Schuster SJ, Diehl JA, Wasick MA: Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase. Blood. 2006, 108: 1744-1750. 10.1182/blood-2006-04-016634PubMedCentralCrossRefPubMed
16.
Krieger S, Gauduchon J, Roussel M, Troussard X, Sola B: Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma. BMC Cancer. 2006, 6: 238- 10.1186/1471-2407-6-238PubMedCentralCrossRefPubMed
17.
Lundquist A, Barré B, Bienvenu F, Hermann J, Avril S, Coqueret O: Kaposi sarcoma-associated viral cyclin K overrides cell growth inhibition mediated by oncostatin M through STAT3 inhibition. Blood. 2003, 101: 4070-4077. 10.1182/blood-2002-07-1994CrossRefPubMed
18.
Lévêque C, Marsaud V, Renoir JM, Sola B: Alternative cyclin D1 forms a and b have different biological functions in the cell cycle of B lymphocytes. Exp Cell Res. 2007, 313: 2719-2729. 10.1016/j.yexcr.2007.04.018CrossRefPubMed
19.
Le Brigand K, Russel R, Moreilhon C, Rouillard J-M, Jost B, Amiot F, Magnone V, Bole-Feysot C, Rostagno P, Virolle V, Defamie V, Dessen P, Williams G, Lyons P, Rios G, Mari B, Gulari E, Kastner P, Gidrol X, Freeman TC, Barbry P: An open-access long oligonucleotide microarray resource for analysis of the human and mouse transcriptomes. Nucleic Acids Research. 2006, 34: e87- 10.1093/nar/gkl485CrossRefPubMed
20.
Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995, 57: 289-300.
21.
Hagedorn M, Zilberberg L, Wilting J, Canron X, Carrabba G, Giussani C, Pluderi M, Bello L, Bikfalvi A: Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Cancer Res. 2002, 62: 6884-6890.PubMed
22.
Hurt EM, Wiestner A, Rosenwald A, Schaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM: Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow. Cancer Cell. 2004, 5: 191-199. 10.1016/S1535-6108(04)00019-4CrossRefPubMed
23.
Li Z, Jiao X, Wang C, Ju X, Lu Y, Yuan L, Lisanti MP, Katiyar S, Pestell RG: Cyclin D1 induction of cellular migration requires p27KIP1. Cancer Res. 2006, 66: 9986-9994. 10.1158/0008-5472.CAN-06-1596CrossRefPubMed
24.
Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T: A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 2004, 64: 3365-3370. 10.1158/0008-5472.CAN-03-2682CrossRefPubMed
25.
Moreno-Bueno G, Rodríguez-Perales S, Sánchez-Estévez C, Hardisson D, Sarrió D, Prat J, Cigudosa JG, Matias-Guiu X, Palacios J: Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene. 2003, 22: 6115-6118. 10.1038/sj.onc.1206868CrossRefPubMed
26.
Benzeno S, Lu F, Guo M, Barbash O, Zhang F, Herman JG, Klein PS, Rustgi A, Diehl JA: Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1. Oncogene. 2006, 25: 6291-6303. 10.1038/sj.onc.1209644CrossRefPubMed
27.
Sakamaki T, Casimiro MC, Ju X, Quong AA, Katiyar S, Liu M, Jiao X, Li A, Zhang X, Lu Y, Wang C, Byers S, Nicholson R, Link T, Shemluck M, Yang J, Fricke ST, Novikoff PM, Papanikolaou A, Arnold A, Albanese C, Pestell R: Cyclin D1 determines mitochondrial function in vivo. Mol Cell Biol. 2006, 26: 5449-5469. 10.1128/MCB.02074-05PubMedCentralCrossRefPubMed
28.
Wang C, Li Z, Lu Y, Du R, Katiyar S, Yang J, Fu M, Leader JE, Quong A, Novikoff PM, Pestell RG: Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proc Natl Acad Sci USA. 2006, 31: 11567-11572. 10.1073/pnas.0603363103. 10.1073/pnas.0603363103CrossRef
29.
Gogvadze V, Orreniius S, Zhivotovsky B: Mitochondria in cancer cells: what is so special about them?. Trends Cell Biol. 2008, 18: 165-173. 10.1016/j.tcb.2008.01.006CrossRefPubMed
30.
Fu M, Wang C, Li Z, Sakamaki T, Pestell RG: Cyclin D1: normal and abnormal functions. Endocrinology. 2005, 145: 5439-5447. 10.1210/en.2004-0959.CrossRef
31.
Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR, Ewen ME: A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 2003, 114: 323-334. 10.1016/S0092-8674(03)00570-1CrossRefPubMed
32.
Gandin V, Miluzio A, Barbieri AM, Beugnet A, Kiyokawa H, Marchisio PC, Biffo S: Eukaryotic initiation factor is rate-limiting in translation, growth and transformation. Nature. 2008, 455: 684-688. 10.1038/nature07267PubMedCentralCrossRefPubMed
33.
Li Z, Wang C, Jiao X, Katiyar S, Casimiro MC, Prendergast GC, Powell MJ, Pestell RG: Alternate cyclin D1 mRNA splicing modulates P27KIP1 binding and cell migration. J Biol Chem. 2008, 283: 7007-7015. 10.1074/jbc.M706992200CrossRefPubMed
34.
Baek K, Brown RS, Birrane G, Ladias JA: Crystal structure of human cyclin K, a positive regulator of cyclin-dependent kinase 9. J Mol Biol. 2007, 366: 563-573. 10.1016/j.jmb.2006.11.057PubMedCentralCrossRefPubMed
35.
Yasui M, Yamamoto H, Ngan CY, Damdinsuren B, Sugita Y, Fukunaga H, Gu J, Maeda M, Takemasa I, Ikeda M, Fujio Y, Sekimoto M, Matsuura N, Weinstein IB, Monden M: Antisense to cyclin D1 inhibits vascular endothelial growth factor - stimulated growth of vascular endothelial cells: implication for tumor development. Clin Cancer Res. 2006, 12: 4720-4729. 10.1158/1078-0432.CCR-05-1213CrossRefPubMed
36.
Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC: Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007, 7: 585-598. 10.1038/nrc2189CrossRefPubMed
37.
Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, Mahtouk K, Hillengass J, Rème T, De Vos J, Hundemer M, Condomines M, Bertsch U, Rossi J-F, Jauch A, Klein B, Möhler T: Induction of angiogenesis by normal and malignant plasma cells. Blood. 2009, 114: 128-143. 10.1182/blood-2008-10-184226CrossRefPubMed
38.
Claudio JO, Masih-Khan E, Tang H, Gonçalves J, Voralia M, Li ZH, Nadeem V, Cukerman E, Francisco-Pabalan O, Liew CC, Woodgett JR, Stewart AK: A molecular compendium of genes expressed in multiple myeloma. Blood. 2002, 100: 2175-2186. 10.1182/blood-2002-01-0008CrossRefPubMed
39.
De Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, Requirand G, Pellet F, Pantesco V, Rème T, Jourdan M, Rossi JF, Ørntoft T, Klein B: Comparison of gene expression between malignant and normal plasma cells with oligonucleotide array. Oncogene. 2002, 21: 6848-6857. 10.1038/sj.onc.1205868CrossRefPubMed
40.
Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan GJ, Anderson KC: Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003, 102: 4505-4511. 10.1182/blood-2003-01-0016.CrossRef
41.
Munshi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F, Mitsiades N, Mitsiades C, Kim RS, Li C, Rajkumar SV, Fonseca R, Bergsagel L, Chauhan D, Anderson KC: Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004, 103: 1799-1806. 10.1182/blood-2003-02-0402CrossRefPubMed
42.
Heller G, Schmidt WM, Ziegler B, Holzer S, Müllauer L, Bilban M, Zielinski CC, Drach J, Zöchbauer-Müller S: Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin in multiple myeloma cells. Cancer Res. 2008, 68: 44-54. 10.1158/0008-5472.CAN-07-2531CrossRefPubMed
43.
Batsche E, Yaniv M, Muchardt C: The human SWI/SNF subunit Brm is a regulator of alternative splicing. Nat Struct Mol Biol. 2006, 13: 22-29. 10.1038/nsmb1030CrossRefPubMed
44.
Sanchez G, Bittencourt D, Laud K, Barbier J, Delattre O, Auboeuf D, Dutertre M: Alteration of cyclin D1 transcript elongation by a mutated transcripion factor up-regulates the oncogenic D1b splice isoform in cancer. Proc Natl Acad Sci USA. 2008, 105: 6004-6009. 10.1073/pnas.0710748105PubMedCentralCrossRefPubMed
45.
Wang Y, Dean JL, Millar EKA, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES: Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res. 2008, 68: 5628-5638. 10.1158/0008-5472.CAN-07-3170CrossRefPubMed
46.
Millar EK, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CE, Witkiewicz A, Musgrove EA, Rui H, Lemarchand L, Setiawan VW, Haiman CA, Knudsen KE, Sutherland RL, Knudsen ES: Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Oncogene. 2009, 28: 1812-1820. 10.1038/onc.2009.13PubMedCentralCrossRefPubMed
Metadata
Title
Cyclin K and cyclin D1b are oncogenic in myeloma cells
Authors
Véronique Marsaud
Guergana Tchakarska
Geoffroy Andrieux
Jian-Miao Liu
Doulaye Dembele
Bernard Jost
Joanna Wdzieczak-Bakala
Jack-Michel Renoir
Brigitte Sola
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-103

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid

Research

Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin

Research

Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives

Research

Replication independent DNA double-strand break retention may prevent genomic instability

Research

Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor

Research

Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits